Prenassi Marco, Arlotti Mattia, Borellini Linda, Bocci Tommaso, Cogiamanian Filippo, Locatelli Marco, Rampini Paolo, Barbieri Sergio, Priori Alberto, Marceglia Sara
Dipartimento di Ingegneria e Architettura, Università Degli Studi di Trieste, Trieste, Italy.
Newronika SpA, Milan, Italy.
Front Neurol. 2021 May 31;12:643841. doi: 10.3389/fneur.2021.643841. eCollection 2021.
Adaptive Deep Brain Stimulation (aDBS) is now considered as a new feasible and effective paradigm to deliver DBS to patients with Parkinson's disease (PD) in such a way that not only stimulation is personalized and finely tuned to the instantaneous patient's state, but also motor improvement is obtained with a lower amount of energy transferred to the tissue. Amplitude-controlled aDBS was shown to significantly decrease the amplitude-driven total electrical energy delivered to the tissue (aTEED), an objective measure of the amount of energy transferred by DBS amplitude to the patient's brain. However, there is no direct evidence of a relationship between aTEED and the occurrence of DBS-related adverse events in humans. In this work, we investigated the correlation of aTEED with the occurrence of levodopa-induced dyskinesias pooling all the data available from our previous experiments using aDBS and cDBS. We retrospectively analyzed data coming from 19 patients with PD undergoing surgery for STN-DBS electrode positioning and participating to experiments involving cDBS and aDBS delivery. Patients were all studied some days after the surgery (acute setting). The aTEED and dyskinesia assessments (Rush Dyskinesia Rating Scale, RDRS) considered in the Med ON-Stim ON condition. We confirmed both that aTEED values and RDRS were significantly lower in the aDBS than in cDBS sessions (aTEED mean value, cDBS: 0.0278 ± 0.0011 j, vs. aDBS: 0.0071 ± 0.0003 j, < 0.0001 Wilcoxon's rank sum; normalized RDRS mean score, cDBS: 0.66 ± 0.017 vs. aDBS: 0.45 ± 0.01, = 0.025, Wilcoxon's rank sum test). In addition, we found a direct significant correlation between aTEED and RDRS (ρ = 0.44, = 0.0032, Spearman's correlation). Our results provide a first piece of evidence that aTEED is correlated to the amount of levodopa-induced dyskinesias in patients with PD undergoing STN-DBS, thus supporting the role of aDBS as feasible and safe alternative to cDBS.
自适应深部脑刺激(aDBS)现在被认为是一种新的可行且有效的治疗范式,用于为帕金森病(PD)患者提供深部脑刺激,其方式不仅使刺激个性化并能根据患者的即时状态进行精细调整,而且能以较低的能量传递到组织来实现运动改善。幅度控制的aDBS已被证明能显著降低传递到组织的幅度驱动总电能(aTEED),这是一种衡量深部脑刺激幅度传递到患者大脑的能量量的客观指标。然而,在人类中,没有直接证据表明aTEED与深部脑刺激相关不良事件的发生之间存在关联。在这项工作中,我们汇总了我们之前使用aDBS和常规深部脑刺激(cDBS)实验的所有可用数据,研究了aTEED与左旋多巴诱导的异动症发生之间的相关性。我们回顾性分析了19例接受手术进行丘脑底核深部脑刺激电极定位并参与涉及cDBS和aDBS治疗实验的帕金森病患者的数据。患者均在手术后数天(急性期)进行研究。在药物开启 - 刺激开启状态下考虑aTEED和异动症评估(拉什异动症评定量表,RDRS)。我们证实,在aDBS治疗期间,aTEED值和RDRS均显著低于cDBS治疗期间(aTEED平均值,cDBS:0.0278±0.0011焦耳,vs. aDBS:0.0071±0.0003焦耳,Wilcoxon秩和检验P < 0.0001;标准化RDRS平均评分,cDBS:0.66±0.017 vs. aDBS:0.45±0.01,Wilcoxon秩和检验P = 0.025)。此外,我们发现aTEED与RDRS之间存在直接显著相关性(ρ = 0.44,P = 0.0032,Spearman相关性)。我们的结果提供了首个证据,表明aTEED与接受丘脑底核深部脑刺激的帕金森病患者中左旋多巴诱导的异动症量相关,从而支持了aDBS作为cDBS可行且安全替代方案的作用。